Docetaxel intratumoral - PolyPid
Alternative Names: OncoPLEX Intratumoral cancer therapy programme - Polypid; PLEXonco intratumoral therapy - PolyPidLatest Information Update: 28 Jan 2025
At a glance
- Originator POLYPID
- Class Antineoplastics; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Glioblastoma
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Solid-tumours in Israel (Intratumoural, Injection)
- 14 Feb 2024 Pharmacodynamics data from a preclinical trial in Solid tumours released by PolyPid
- 03 Jun 2022 Pharmacodynamics data preclinical study in Solid tumours presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)